Pharmaceutical Technology
SEPTEMBER 19, 2024
An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual differences in genes, environments, and lifestyles to drive better outcomes through medicine.
Bio Pharma Dive
SEPTEMBER 19, 2024
Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 19, 2024
Home Editorial Services Interview Q&A Chronicle Specials Pharma Mart ePharmail Archives Join Pharma | Login Home > TopNews you can get e-magazine links on WhatsApp.
Bio Pharma Dive
SEPTEMBER 19, 2024
GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster than by current methods with a simpler process.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharma Times
SEPTEMBER 19, 2024
There is currently no national screening programme for the disease in the UK
Bio Pharma Dive
SEPTEMBER 19, 2024
According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
SEPTEMBER 19, 2024
In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future.
Pharmaceutical Technology
SEPTEMBER 19, 2024
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.
Bio Pharma Dive
SEPTEMBER 19, 2024
Shares dropped by as much as one-quarter Thursday after the biotech shared longer-term results for a gene therapy it’s developing for wet AMD.
Pharmaceutical Technology
SEPTEMBER 19, 2024
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
SEPTEMBER 19, 2024
From truckloads of torn documents to avian incursions in the production plant, Granules India’s recent manufacturing reprimand from the FDA is alarming no matter which way you look at it. | Earlier this month, Granules was slapped with a Form 483 following an inspection of its Telangana facility in India that ran from Aug. 26 to Sept. 6. The FDA’s report cites six observations around poor quality control procedures, subpar cleaning, cross-contamination risks and more.
Pharmaceutical Technology
SEPTEMBER 19, 2024
Statistics show incidences of cancer are rising in younger demographics.
pharmaphorum
SEPTEMBER 19, 2024
Neuralink gets FDA breakthrough status for an implantable chip called Blindsight that promises to restore eyesight to the blind
Pharmaceutical Technology
SEPTEMBER 19, 2024
Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of HER2-overexpressing cancers.
pharmaphorum
SEPTEMBER 19, 2024
FDA turns down Vanda Pharma's tradipitant for gastroparesis, prompting a furious response from the company
Pharmaceutical Technology
SEPTEMBER 19, 2024
Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in India.
pharmaphorum
SEPTEMBER 19, 2024
ICER will preempt the next Medicare drug pricing round with a 'special report' on two COPD drugs from GSK
Pharmaceutical Technology
SEPTEMBER 19, 2024
The US FDA has granted approval for MSD’s KEYTRUDA regimen as a first-line treatment for malignant pleural mesothelioma (MPM).
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Patent Watch
SEPTEMBER 19, 2024
The generic drug market in the United States is characterized by significant price volatility and shortages, driven by the structure of the market and the incentives for manufacturers. To address these issues, several market-based proposals have been put forth to optimize generic drug cost and availability.
Pharmaceutical Technology
SEPTEMBER 19, 2024
Gavi has entered into an agreement with Bavarian Nordic to secure 500,000 doses of the MVA-BN mpox vaccine.
pharmaphorum
SEPTEMBER 19, 2024
Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, seeking funds for its rival to respiratory drug Tezspire.
Fierce Pharma
SEPTEMBER 19, 2024
A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migra | A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migraines than a previous class of medicines.
pharmaphorum
SEPTEMBER 19, 2024
Explore how the pharmaceutical industry is ensuring supply chain resilience to maintain consistency despite global events. Learn more about strategies and practices implemented to address challenges and ensure reliable delivery of pharmaceutical products.
XTalks
SEPTEMBER 19, 2024
World Cancer Research Day 2024, observed on September 24, highlights innovation under the theme “Innovation In Cancer Research Drives Progress Toward Health Equity.” This year’s theme focuses on the need for breakthroughs across all stages of cancer care, from prevention to treatment. As new research reaches more patients, thanks to policies and technological advancements, it’s improving survival rates and bringing us closer to health equity around the world. 2024 has seen significant US F
BioPharma Reporter
SEPTEMBER 19, 2024
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive, HER2-negative) stage two or three early breast cancer, who are at high risk of cancer recurrence.
Outsourcing Pharma
SEPTEMBER 19, 2024
The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met its primary endpoint.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
SEPTEMBER 19, 2024
Respiratory medicine is one frontier of the global healthcare landscape which has undergone significant transformations in recent years. | AstraZeneca's Maria Belvisi explores innovative approaches in respiratory medicine, from AI-driven trials to next-gen therapeutics.
BioPharma Reporter
SEPTEMBER 19, 2024
Although vaccines already exist to prevent mpox, high prices and the risk of side effects make it difficult to roll them out in the regions that need them most. Vaccine developers are working to offer better options.
Fierce Pharma
SEPTEMBER 19, 2024
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma. | Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the cell therapy-focused joint venture with Fosun Pharma.
pharmaphorum
SEPTEMBER 19, 2024
Daiichi Sankyo's FLT3 inhibitor Vanflyta has been recommended for NHS use as a treatment for a specific form of acute myeloid leukaemia (AML) in England and Wales, the first countries in Europe to authorise use of the drug after a health technology assessment (HTA) review.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
264 
Let's personalize your content